Published in Int J Cancer on June 15, 2010
The Emerging Hallmarks of Cancer Metabolism. Cell Metab (2016) 2.32
GPRC6A regulates prostate cancer progression. Prostate (2011) 1.68
Estrogen-regulated genes in rat testes and their relationship to recovery of spermatogenesis after irradiation. Biol Reprod (2011) 1.42
A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. Br J Cancer (2010) 1.23
Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma. Cell Death Dis (2013) 1.16
Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges. Cancer Res Treat (2013) 1.13
Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase. Br J Cancer (2011) 1.05
Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction. Mol Cancer Ther (2013) 1.05
Multiligand specificity and wide tissue expression of GPRC6A reveals new endocrine networks. Endocrinology (2012) 1.03
Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis. Nature (2015) 1.03
Glutamine-fueled mitochondrial metabolism is decoupled from glycolysis in melanoma. Pigment Cell Melanoma Res (2012) 1.00
Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. Cell Death Dis (2012) 1.00
SLC6A14 (ATB0,+) protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer. J Biol Chem (2011) 0.99
Arginase in retinopathy. Prog Retin Eye Res (2013) 0.94
Proteomic analysis of oropharyngeal carcinomas reveals novel HPV-associated biological pathways. Int J Cancer (2012) 0.94
Modeling cancer metabolism on a genome scale. Mol Syst Biol (2015) 0.92
Extensive decoupling of metabolic genes in cancer. PLoS Comput Biol (2015) 0.91
Crystal structures of complexes with cobalt-reconstituted human arginase I. Biochemistry (2011) 0.86
Mesothelioma: a review. Ochsner J (2012) 0.86
Recombinant human arginase induced caspase-dependent apoptosis and autophagy in non-Hodgkin's lymphoma cells. Cell Death Dis (2013) 0.86
Arginine deprivation and autophagic cell death in cancer. Proc Natl Acad Sci U S A (2014) 0.84
Nitric oxide synthase inhibition enhances the antitumor effect of radiation in the treatment of squamous carcinoma xenografts. PLoS One (2011) 0.83
A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas. Cell Death Dis (2016) 0.83
Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions. Cancer Discov (2016) 0.82
Human enteroendocrine cell responses to infection with Chlamydia trachomatis: a microarray study. Gut Pathog (2014) 0.81
Altered metabolite levels in cancer: implications for tumour biology and cancer therapy. Nat Rev Cancer (2016) 0.80
Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling. BMC Cancer (2014) 0.80
Graphene Functionalized with Arginine Decreases the Development of Glioblastoma Multiforme Tumor in a Gene-Dependent Manner. Int J Mol Sci (2015) 0.80
Argininosuccinate synthetase 1 suppression and arginine restriction inhibit cell migration in gastric cancer cell lines. Sci Rep (2015) 0.80
Arginine deprivation affects glioblastoma cell adhesion, invasiveness and actin cytoskeleton organization by impairment of β-actin arginylation. Amino Acids (2014) 0.79
Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy. BMC Cancer (2014) 0.79
Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer. J Exp Clin Cancer Res (2014) 0.78
Increased expression of argininosuccinate synthetase protein predicts poor prognosis in human gastric cancer. Oncol Rep (2014) 0.78
Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights. World J Gastroenterol (2014) 0.78
Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia. Br J Cancer (2015) 0.77
Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo. Cancer Biol Ther (2015) 0.76
Arginine Metabolism in Bacterial Pathogenesis and Cancer Therapy. Int J Mol Sci (2016) 0.76
Analysis of Gene Expression in 3D Spheroids Highlights a Survival Role for ASS1 in Mesothelioma. PLoS One (2016) 0.76
Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas. J Pathol Clin Res (2014) 0.76
Single amino acid arginine deprivation triggers prosurvival autophagic response in ovarian carcinoma SKOV3. Biomed Res Int (2014) 0.76
Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1. Cell Rep (2016) 0.75
Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma. PLoS One (2017) 0.75
(13)C and (15)N natural isotope abundance reflects breast cancer cell metabolism. Sci Rep (2016) 0.75
Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts. Respir Res (2017) 0.75
Metabolic reprogramming in clear cell renal cell carcinoma. Nat Rev Nephrol (2017) 0.75
Therapeutic interventions to disrupt the protein synthetic machinery in melanoma. Pigment Cell Melanoma Res (2015) 0.75
Metabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes. Oncotarget (2016) 0.75
Mesothelioma treatment: Are we on target? A review. J Adv Res (2014) 0.75
L-Canavanine potentiates the cytotoxicity of doxorubicin and cisplatin in arginine deprived human cancer cells. PeerJ (2016) 0.75
Argininosuccinate lyase interacts with cyclin A2 in cytoplasm and modulates growth of liver tumor cells. Oncol Rep (2016) 0.75
Expression profile and down-regulation of argininosuccinate synthetase in hepatocellular carcinoma in a transgenic mouse model. J Biomed Sci (2015) 0.75
PEGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration. Oncotarget (2017) 0.75
[Tumor pathophysiology]. Strahlenther Onkol (2012) 0.75
NMR metabolomics highlights sphingosine kinase-1 as a new molecular switch in the orchestration of aberrant metabolic phenotype in cancer cells. Mol Oncol (2017) 0.75
DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell (2006) 9.47
"Re-educating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med (2008) 4.38
Small-cell lung cancer. Lancet (2011) 3.61
p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell (2003) 2.65
Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature (2007) 2.54
Five additional Costello syndrome patients with rhabdomyosarcoma: proposal for a tumor screening protocol. Am J Med Genet (2002) 2.50
The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J Biol Chem (2001) 2.47
Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol (2004) 2.43
iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet (2003) 2.41
SNPnexus: a web database for functional annotation of newly discovered and public domain single nucleotide polymorphisms. Bioinformatics (2008) 2.40
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res (2006) 2.35
Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci (2003) 2.29
iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet (2006) 2.20
The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nat Struct Mol Biol (2007) 2.13
Identification of novel isoforms of the BH3 domain protein Bim which directly activate Bax to trigger apoptosis. Mol Cell Biol (2002) 2.10
Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol (2002) 2.08
Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma. J Invest Dermatol (2013) 2.08
Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol (2011) 2.06
Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids. Am J Respir Cell Mol Biol (2008) 1.99
A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell (2011) 1.95
HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation. Am J Med Genet A (2006) 1.94
The p53 pathway in breast cancer. Breast Cancer Res (2002) 1.94
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell (2008) 1.90
ASPP1 and ASPP2: common activators of p53 family members. Mol Cell Biol (2004) 1.88
Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent. J Pathol (2003) 1.83
Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol (2009) 1.77
MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer (2010) 1.74
Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis. Int J Cancer (2004) 1.68
Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene (2002) 1.67
Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene (2004) 1.64
Interleukin-1beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite. Int J Oncol (2004) 1.61
Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology (2005) 1.61
Pancreatic Expression database: a generic model for the organization, integration and mining of complex cancer datasets. BMC Genomics (2007) 1.56
The bladder pain/interstitial cystitis symptom score: development, validation, and identification of a cut score. Eur Urol (2011) 1.55
A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin Cancer Res (2004) 1.54
SNPnexus: a web server for functional annotation of novel and publicly known genetic variants (2012 update). Nucleic Acids Res (2012) 1.45
Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One (2013) 1.45
Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clin Cancer Res (2005) 1.44
Role of Bim in the survival pathway induced by Raf in epithelial cells. Oncogene (2004) 1.43
Using BioMart as a framework to manage and query pancreatic cancer data. Database (Oxford) (2011) 1.43
In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res (2006) 1.42
Paternal bias in parental origin of HRAS mutations in Costello syndrome. Hum Mutat (2006) 1.39
Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum Gene Ther (2002) 1.39
Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery. Int J Gynecol Cancer (2012) 1.37
Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer's disease. Cell (2012) 1.36
S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer. Cancer Res (2007) 1.33
Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies. Blood (2005) 1.31
Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. J Clin Invest (2010) 1.30
The p53 network in head and neck cancer. Oral Oncol (2003) 1.30
Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles. Viruses (2010) 1.30
Two nonconsensus sites in the Epstein-Barr virus oncoprotein EBNA3A cooperate to bind the co-repressor carboxyl-terminal-binding protein (CtBP). J Biol Chem (2002) 1.28
Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res (2009) 1.28
AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of cathepsins B and D. Cancer Res (2011) 1.26
Further delineation of cardiac abnormalities in Costello syndrome. Am J Med Genet (2002) 1.26
New advances in the second-line treatment of small cell lung cancer. Oncologist (2009) 1.25
Twenty-five years' clinical experience with placental site trophoblastic tumors. J Reprod Med (2002) 1.25
Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio-facio-cutaneous syndrome from Costello syndrome. Am J Med Genet A (2007) 1.24
Somatic mosaicism for an HRAS mutation causes Costello syndrome. Am J Med Genet A (2006) 1.21
Costello syndrome associated with novel germline HRAS mutations: an attenuated phenotype? Am J Med Genet A (2008) 1.21
Frontometaphyseal dysplasia: mutations in FLNA and phenotypic diversity. Am J Med Genet A (2006) 1.20
Concomitant inactivation of p53 and Chk2 in breast cancer. Oncogene (2002) 1.19
Fibroblast growth factor 2-mediated translational control of IAPs blocks mitochondrial release of Smac/DIABLO and apoptosis in small cell lung cancer cells. Mol Cell Biol (2003) 1.19
Online resources of cancer data: barriers, benefits and lessons. Brief Bioinform (2010) 1.19
Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res (2007) 1.19
Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial. J Thorac Oncol (2013) 1.17
Rapid infusion of rituximab over 60 min. Eur J Haematol (2009) 1.17
Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer (2009) 1.15
Ser392 phosphorylation regulates the oncogenic function of mutant p53. Cancer Res (2004) 1.14
Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics (2003) 1.14
Management of brain metastases in patients with high-risk gestational trophoblastic tumors. J Reprod Med (2002) 1.13
The role of S100P in the invasion of pancreatic cancer cells is mediated through cytoskeletal changes and regulation of cathepsin D. Cancer Res (2007) 1.09
Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal. Mol Ther (2004) 1.08
p16INK4a and p14ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma. J Invest Dermatol (2004) 1.08
Male-to-male transmission of Costello syndrome: G12S HRAS germline mutation inherited from a father with somatic mosaicism. Am J Med Genet A (2009) 1.08
Coincident inactivation of 14-3-3sigma and p16INK4a is an early event in vulval squamous neoplasia. Oncogene (2002) 1.07
Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol (2006) 1.07
Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2'-deoxycytidine treatment is associated with activation of the interferon signalling pathway. Oncogene (2005) 1.06
Why does cytotoxic chemotherapy cure only some cancers? Nat Clin Pract Oncol (2008) 1.04
Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL. Cancer Res (2008) 1.04
The Pancreatic Expression database: 2011 update. Nucleic Acids Res (2010) 1.04
Longitudinal assessment of cognitive characteristics in Costello syndrome. Am J Med Genet A (2007) 1.03
Analysis of the urine proteome in patients with pancreatic ductal adenocarcinoma. Proteomics Clin Appl (2008) 1.03
Observation of a parental inversion variant in a rare Williams-Beuren syndrome family with two affected children. Hum Genet (2005) 1.03
Combination of microdissection and microarray analysis to identify gene expression changes between differentially located tumour cells in breast cancer. Oncogene (2003) 1.02
AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clin Cancer Res (2009) 1.02
Salmonella enterica serovar Typhimurium interaction with dendritic cells: impact of the sifA gene. Cell Microbiol (2004) 1.01
The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma. AIDS (2009) 1.01
Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity. Cancer Res (2002) 1.00
Epigenetic inactivation implies a tumor suppressor function in hematologic malignancies for Polo-like kinase 2 but not Polo-like kinase 3. Cell Cycle (2006) 1.00
Subtelomeric deletions of chromosome 9q: a novel microdeletion syndrome. Am J Med Genet A (2004) 0.99
Genome-wide analysis of pancreatic cancer using microarray-based techniques. Pancreatology (2008) 0.98
Polyomavirus enhancer activator 3 protein promotes breast cancer metastatic progression through Snail-induced epithelial-mesenchymal transition. J Pathol (2011) 0.98
Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent. Eur J Cancer (2011) 0.98
Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain. Proc Natl Acad Sci U S A (2014) 0.98
Gene expression meta-analysis identifies VDAC1 as a predictor of poor outcome in early stage non-small cell lung cancer. PLoS One (2011) 0.98
p53 family members and chemoresistance in cancer: what we know and what we need to know. Drug Resist Updat (2003) 0.97
PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer. J Pathol (2011) 0.97